

The opportunity analysis can be better understood under the following heads:

1. Present status and number of HIV infected patients in the world.
2. Treatment available towards AIDS
3. Pharma Industry overview regarding AIDS treatment
4. Investment overview regarding AIDS worldwide
5. Anupam Herbals AIDS medicine and its USP as Allo-Ayurvedic medicine.

1. *Present Status and number of HIV infected patients in the world :*

As per UNAIDS (NGO working on AIDS, United Nations) data, covering 160 countries over the world,

GLOBAL STATISTICS—2015

- 17 million people were accessing antiretroviral therapy
- 36.7 million [34.0 million–39.8 million] people globally were living with HIV
- 2.1 million [1.8 million–2.4 million] people became newly infected with HIV
- 1.1 million [940 000–1.3 million] people died from AIDS-related illnesses
- 78 million [69.5 million–87.6 million] people have become infected with HIV since the start of the epidemic
- 35 million [29.6 million–40.8 million] people have died from AIDS-related illnesses since the start of the epidemic

People living with HIV

- In 2015, there were 36.7 million [34.0 million–39.8 million] people living with HIV.

People living with HIV accessing antiretroviral therapy

- As of December 2015, 17 million people living with HIV were accessing antiretroviral therapy, up from 15.8 million in June 2015 and 7.5 million in 2010.
 - 46% [43–50%] of all adults living with HIV were accessing treatment in 2015, up from 23% [21–25%] in 2010.
 - 49% [42–55%] of all children living with HIV were accessing treatment in 2015, up from 21% [18–23%] in 2010.
 - 77% [69–86%] of pregnant women living with HIV had access to antiretroviral medicines to prevent transmission of HIV to their babies in 2015.

New HIV infections

- New HIV infections have fallen by 6% since 2010.
 - Worldwide, 2.1 million [1.8 million–2.4 million] people became newly infected with HIV in 2015, down from 2.2 million [2 million–2.5 million] in 2010.
- New HIV infections among children have declined by 50% since 2010.
 - Worldwide, 150 000 [110 000–190 000] children became newly infected with HIV in 2015, down from 290 000 [250 000–350 000] in 2010.
 -

AIDS-related deaths

- AIDS-related deaths have fallen by 45% since the peak in 2005.
 - In 2015, 1.1 million [940 000–1.3 million] people died from AIDS-related causes worldwide, compared to 2 million [1.7 million–2.3 million] in 2005.

HIV/tuberculosis

- Tuberculosis-related deaths among people living with HIV have fallen by 32% since 2004.
 - Tuberculosis remains the leading cause of death among people living with HIV, accounting for around one in three AIDS-related deaths.
 - In 2014, the percentage of identified HIV-positive tuberculosis patients who started or continued on antiretroviral therapy reached 77%.

	People living with HIV (all ages)		New HIV infections (all ages)	
	2010	2015	2010	2015
Global	33.3 million [30.9 million–36.1 million]	36.7 million [34.0 million–39.8 million]	2.2 million [2.0 million–2.5 million]	2.1 million [1.8 million–2.4 million]
Asia and Pacific	4.7 million [4.1 million–5.5 million]	5.1 million [4.4 million–5.9 million]	310 000 [270 000–360 000]	300 000 [240 000–380 000]
Eastern and southern Africa	17.2 million [16.1 million–18.5 million]	19.0 million [17.7 million–20.5 million]	1.1 million [1.0 million–1.2 million]	960 000 [830 000–1.1 million]
Eastern Europe and central Asia	1.0 million [950 000–1.1 million]	1.5 million [1.4 million–1.7 million]	120 000 [110 000–130 000]	190 000 [170 000–200 000]
Latin America and the Caribbean	1.8 million [1.5 million–2.1 million]	2.0 million [1.7 million–2.3 million]	100 000 [86 000–120 000]	100 000 [86 000–120 000]
Middle East and North Africa	190 000 [150 000–240 000]	230 000 [160 000–330 000]	20 000 [15 000–29 000]	21 000 [12 000–37 000]
Western and central Africa	6.3 million [5.2 million–7.7 million]	6.5 million [5.3 million–7.8 million]	450 000 [350 000–560 000]	410 000 [310 000–530 000]
Western and central Europe and North America	2.1 million [1.9 million–2.3 million]	2.4 million [2.2 million–2.7 million]	92 000 [89 000–97 000]	91 000 [89 000–97 000]

2. Treatment available towards AIDS

Allopathy Medicines – Antiretroviral Therapy is available for AIDS – HIV infections worldwide.

Antiretroviral therapy (ART) is the use of HIV medicines to treat HIV infection. People on ART take a combination of HIV medicines (called an HIV regimen) every day. ART is recommended for everyone infected with HIV. ART can't cure HIV. The ART do not kill or cure virus.


- Potential risks of ART include unwanted side effects from HIV medicines and [drug interactions](#) between HIV medicines or between HIV medicines and other medicines a person is taking. Poor adherence—not taking HIV medicines every day and exactly as prescribed—can lead to [drug resistance](#) and treatment failure.

Side effects

Side effects from HIV medicines can vary depending on the medicine and the person taking the medicine. People taking the same HIV medicine can have very different side effects. Some side effects, for example, headache or occasional dizziness, may not be serious. Other side effects, such as swelling of the mouth and tongue or liver damage, can be life-threatening.

Drug interactions

HIV medicines can interact with other HIV medicines in an HIV regimen. They can also interact with other medicines that a person with HIV is taking. A drug interaction can reduce or increase a medicine's effect on the body. Drug interactions can also cause unwanted side effects.



Drug resistance

When HIV multiplies in the body, the virus sometimes mutates (changes form) and makes variations of itself. Variations of HIV that develop while a person is taking HIV medicines can lead to drug-resistant strains of HIV. HIV medicines that previously controlled a person's HIV are not effective against the new, drug-resistant HIV. In other words, the person's HIV continues to multiply.

3. Pharma industry overview regarding AIDS treatment :

Lack of money is an obvious challenge, although a great deal of aid is distributed throughout developing countries with high HIV/AIDS rates.

For African countries with advanced medical facilities, [patents](#) on many drugs have hindered the ability to make low cost alternatives.

[VaxGen](#), a California company, has come up with the most advanced vaccine called AIDS-VAX, but this has only been found effective in the Asian and black populations, thus funding for further research for this has been lacking since money cannot be obtained from

poor African governments, and once it is found, the vaccine would not be able to be made, the costs would be prohibitive to poor Asian and Africans.

4. Investment Overview Regarding AIDS worldwide :

- At the end of 2015, US\$ 19 billion was invested in the AIDS response in low- and middle-income countries (not including the countries that have recently transitioned into high-income categories).
- Domestic resources constituted 57% of the total resources for HIV in low- and middle-income countries in 2015.
- Recent updated UNAIDS estimates indicate that US\$ 26.2 billion will be required for the AIDS response in 2020, with US\$ 23.9 billion required in 2030.

5. ANUPAM HERBALS AIDS medicines :

We have formulated an Ayurvedic formulation for AIDS. This formulation is based on the ancient Ayurvedic science and components are well specified in our ancient original Ayurvedic text. Worldwide this product is registered internationally under herbals.

Based on our research (of around 15 years), studies and clinical trials (AS verified in Government approved center IFAKARA, Tanzania), we have set the dosage, combinations of contents and methodology of application which are safe, unique and do wonder in AIDS patients.

We have observed that we have been able to arrest and control the disease at a point thus making the patient normal and healthy, within 2months time as done by other available antiretroviral today.

But added advantage where this product get opportunity to compete their present day competitors is to boosts and start to revert back Patient's immunity (cd4/cd8 count) within one to two months and make patient healthy as normal as we people. The patient will start to regain weight after 15 days to one month time from the time they start to take AH-IMMUCURE ABC.

Unlike Allopathic medication, as is the nature of Ayurvedic formulations, there are minimal side effects compared to other available treatment and more easily acceptable by patients.

As of today, no other company in the market can lay claim to this stage of healing even (as already claim verified by IFKARA, Tanzania AFRICA) though many false claims exist in large numbers.

Definitely few limitation are there as treating doctor must treat Secondary infection like Tuberculosis, dermal infections or gastroenteritis etc. to avoid exhaustion on immunity regained after taken AH-IMMUCURE ABC.

